Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Stock Rating Upgraded by Barclays

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was upgraded by Barclays from an “equal weight” rating to an “overweight” rating in a research report issued to clients and investors on Tuesday.

Several other analysts have also weighed in on the stock. Morgan Stanley upgraded shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research note on Wednesday, December 3rd. Zacks Research cut Bayer Aktiengesellschaft from a “strong-buy” rating to a “hold” rating in a report on Monday, November 3rd. Finally, JPMorgan Chase & Co. raised Bayer Aktiengesellschaft from a “neutral” rating to an “overweight” rating in a report on Monday, December 8th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy”.

Bayer Aktiengesellschaft Stock Performance

Shares of OTCMKTS BAYRY traded down $0.07 during trading hours on Tuesday, reaching $11.10. 287,857 shares of the stock were exchanged, compared to its average volume of 557,025. The firm has a market capitalization of $43.60 billion, a price-to-earnings ratio of -123.26, a P/E/G ratio of 5.48 and a beta of 0.66. The stock’s fifty day simple moving average is $9.27 and its 200 day simple moving average is $8.45. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.73 and a current ratio of 1.13. Bayer Aktiengesellschaft has a 52 week low of $4.96 and a 52 week high of $11.17.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.